Credit: ACROBiosystems

On October 18, 2021, ACROBiosystems listed on Shenzhen Stock Exchange (SZSE) ChiNext. The issue price is RMB 112.5 per share, and the opening price is RMB 198 per share. The total amount of funds to be raised is 2.25 billion yuan.

Credit: ACROBiosystems

Credit: ACROBiosystems

ACROBiosystems was established in 2010. It is a high-tech enterprise specializing in providing recombinant protein and other key biological reagent products and technical services, helping global biomedical companies, biotechnology companies and scientific research institutions to conduct biological drugs, cellular immunotherapy and Development and production of diagnostic reagents.

The company’s main products and services are used in early drug discovery and verification, drug screening and optimization, diagnostic reagent development and optimization, preclinical and clinical trials, drug production processes and Process control (CMC) and other R&D and production links.

From January to June 2021, ACROBiosystems achieved operating income of 175 million yuan, an increase of 76.43% over the same period in 2020. Among them, from January to June 2021, the company's COVID-19 product sales revenue was 48,580,300 yuan, sales revenue except COVID-19 product was 127 million yuan, and COVID-19 product revenue accounted for 27.74%. After deducting COVID-19 products, the revenue of non-COVID-19 products from January to June 2021 increased by 75.82% compared with the same period in 2020.